EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Anthony R Mato, Jennifer A Woyach, Jennifer R Brown iD, Paolo Ghia, Krish Patel iD, Toby A Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S Tam, Nirav N Shah iD, Catherine C Coombs und 23 weitere

New England Journal of Medicine · 06.07.2023 · 389 (1) · 33-44

DOI: 10.1056/nejmoa2300696 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 06.07.2023. Verfasst von Anthony R Mato und 34 weiteren Autor:innen. Beteiligte Einrichtung: From Memorial Sloan Kettering Cancer Center (A.R.M.), and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (N.L.), New …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors. Die Arbeit wurde bisher 240-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsHumansHemorrhageNeutropeniaProgression-Free SurvivalAgammaglobulinaemia Tyrosine KinasePyrazoles

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinasepirtobrutinibPyrazolesBTK protein, human

Autor:innen und Institutionen

  • From Memorial Sloan Kettering Cancer Center (A.R.M.), and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (N.L.), New York, the Donald and Barbara Zucker School of Medicine, Northwell-Hofs…

ORCID-Profile: Jennifer R Brown, Krish Patel, Nirav N Shah, Chan Y Cheah, Alvaro J Alencar, John F Seymour

Förderung

  • Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company.

Zitieren

APA

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Shah, N. N., Coombs, C. C., Ujjani, C. S., Fakhri, B., Cheah, C. Y., Patel, M. R., Alencar, A. J., Cohen, J. B., Gerson, J. N., …, & Jurczak, W. (2023). Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 389(1), 33-44. https://doi.org/10.1056/nejmoa2300696

Vancouver

Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2023;389(1):33-44. doi:10.1056/nejmoa2300696

BibTeX
@article{Mato2023,
  author = {Mato, Anthony R and Woyach, Jennifer A and Brown, Jennifer R and Ghia, Paolo and Patel, Krish and Eyre, Toby A and Munir, Talha and Lech-Maranda, Ewa and Lamanna, Nicole and Tam, Constantine S and Shah, Nirav N and Coombs, Catherine C and Ujjani, Chaitra S and Fakhri, Bita and Cheah, Chan Y and Patel, Manish R and Alencar, Alvaro J and Cohen, Jonathon B and Gerson, James N and Flinn, Ian W and Ma, Shuo and Jagadeesh, Deepa and Rhodes, Joanna M and Hernandez-Ilizaliturri, Francisco and Zinzani, Pier L and Seymour, John F and Balbas, Minna and Nair, Binoj and Abada, Paolo and Wang, Chunxiao and Ruppert, Amy S and Wang, Denise and Tsai, Donald E and Wierda, William G and Jurczak, Wojciech},
  title = {Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {1},
  pages = {33--44},
  doi = {10.1056/nejmoa2300696}
}
Kostenlos starten →